In these studies we showed that 17β-E
2 at pharmacologic concentrations prevented the accumulation of ROS, collapse of mitochondrial potential, loss of cellular ATP, and apoptosis of the RPE cells caused by oxidative stress. We also showed that the protection of mitochondria by 17β-E
2 is ER dependent because the ER antagonist (ICI 182170) blocks the beneficial effects. ICI is a pure antagonist of ER and leads to the degradation of ER receptors.
22 Therefore, we infer that the lack of protective effect in the presence of ICI is due to the lack of ER in the cells after treatment. Additionally 17α-E
2, a weak ERα ligand, provided only marginal protection compared with 17β-E
2, indicating a requirement for tight binding with the receptor. These data indicate that 17β-E
2 protects mitochondria in ARPE-19 cells through a specific receptor-mediated mechanism. Several reports have shown that estrogens protect mitochondria in human lens epithelial cells (HLECs) from H
2O
2 death.
20,23,24 The molecular mechanism of protection in HLECs was a rapid nongenomic-type response and was ER dependent.
Estrogens mediate their physiological effects through two subtypes of receptors, ERα and ERβ. These are nuclear receptors that, on ligand binding, translocate to the nucleus and modulate gene expression.
25 Although few studies suggest that ERβ acts as a negative regulator of ERα,
26,27 the role of ERβ in cellular physiology is not clearly understood. Βoth ER subtypes are expressed in the male and female retina.
28,29 Similar to these studies, our RNA and protein expression results confirmed that ERα and ERβ are expressed in the RPE. To identify which of the ER subtypes is required for protecting RPE from oxidative stress, we used ER subtype-specific antagonists and targeted knockdown of ER gene expression. Our results show that antagonists that block ERβ (ICI or THC) completely abrogated the beneficial effects of 17β-E
2. Preincubation with tamoxifen (ERα antagonist) reversed the effect of 17α-E2 (ERα agonist) but did not block 17β-E
2–mediated cytoprotection. Barkhem et al.
30 showed that 17α-E2 has partial agonism in 293/hERβ cells and full agonist activity in 293/hERα cells. These results indicate that the mild protection seen with 17α-E2 is probably an ERα-mediated effect. Further, siRNA knockdown of ERβ gene expression, but not ERα gene expression, resulted in the loss of mitochondrial potential even in the presence of 17β-E
2. These data indicate that 17β-E
2 mediates its protection by engaging ERβ but not ERα. This is the first report to elucidate the role of ERβ in protecting mitochondria in RPE cells from oxidative damage. Previously, it had been demonstrated that ERβ plays an important role in regulating extracellular matrix turnover during oxidant injury in RPE both in vitro and in vivo.
14,31 These observations indicate that ERβ can protect RPE from oxidative stress through multiple mechanisms.
ERβ was shown to localize to the mitochondria of HLECS and protect the cells from oxidative stress.
24 In RPE cells, unliganded ERβ was distributed in the cytoplasm, nuclei, and mitochondria, similar to the localization of the wild-type receptor in HLECs.
24 During oxidative stress, the receptor predominantly colocalized with the collapsed mitochondria in the perinuclear region. In cells pretreated with 17β-E
2, mitochondrial membrane potential was preserved and there was increased ERβ receptor colocalization with the mitochondria as early as 4 hours. At this time point, there was a fourfold increase in transcript levels of ERβ, but protein levels were increased only 8 hours after exposure. These data, along with our subcellular fractionation results (
Fig. 7E), indicate that at the earlier time points, 17β-E
2 may stabilize the mitochondrial ERβ levels or induce translocation of ERβ to the mitochondria. Although the exact mechanism by which mitochondria-associated ERβ protects RPE cells from oxidative stress is unknown, we speculate that ERβ and possibly estrogen bound to the receptor associate with the mitochondrial permeability transition pore and stabilize the mitochondrial membrane, similar to that suggested for HLECs.
24
Estrogens, estrogen metabolites, and phytoestrogens have been reported to induce phase II detoxification enzymes in myocardial cells,
32 IMR-32 cells,
33 and HepG2 cells.
34 Phase II proteins such as HO-1 and GPx neutralize the reactive oxygen species and protect the cells from oxidative injury. These proteins provide cells with the ability to mount a prolonged and sustained defense against the deleterious effect of oxidants such as superoxide and H
2O
2. In our study, 17β-E
2 upregulated HO-1 and GPx2 gene expression in H
2O
2-stressed cells, and this induction was inhibited by ER antagonist ICI, indicating a receptor-mediated regulation of gene expression. Previous studies have shown both ER-dependent and -independent mechanisms for HO-1 expression. In H9c2 myocardial cells
32 and HepG2 cells,
34 the expression of phase II genes was ER dependent, but in IMR-32 cells,
33 the ER was not required for phase II gene expression.
Apart from the effect on phase II genes, we also show that 17β-E
2 modulates intracellular levels of SOD. SOD is an enzyme that is involved in the cellular defense against oxidative stress by detoxification of ROS. SOD has three isoforms, cytosolic Cu/Zn SOD (Cu/ZnSOD), mitochondrial manganese SOD (MnSOD), and extracellular SOD (ecSOD). Reduction in MnSOD levels is associated with disruption of mitochondrial function, accelerated DNA strand breakage, and precocious neuronal degeneration.
35 In our study, H
2O
2 stress reduced the levels of the mitochondrial MnSOD by more than 50%, indicating that this could be a contributing factor to mitochondrial dysfunction. 17β-E
2 treatment significantly alleviated the loss of MnSOD and of Cu/Zn SOD in H
2O
2-treated cells, indicating an additional role for estrogens in maintaining cellular antioxidant function.
In summary, our data suggest that activation of ERβ protects RPE cells from oxidative damage in two phases, a quick or immediate phase that involves rapid translocation of ligand-receptor complex to mitochondria to protect the mitochondrial pore and function and a prolonged but more sustained phase that involves upregulation of ERβ and phase II antioxidant genes such as HO-1 and GPx2. Our results suggest that the effects of 17β-E2 are ERβ specific and open avenues for using selective ERβ ligands for reducing oxidative stress, an important factor in the pathogenesis of AMD.